Added to YB: 2025-10-28
Pitch date: 2025-10-24
2367.HK [bullish]
Giant Biogene Holding Co., Ltd.
-16.79%
current return
Author Info
Ridire Research is an independent equity research platform focused on actionable, high-conviction long/short equity ideas. We combine fundamental rigor with quantitative structure to identify mispriced opportunities others overlook. Sign up for the newsletter.
Company Info
Giant Biogene Holding Co., Ltd., an investment holding company, designs, develops, manufactures, and sells skin treatment products with recombinant collagen in the People’s Republic of China.
Market Cap
HKD 40.9B
Pitch Price
HKD 42.18
Price Target
N/A
Dividend
3.13%
EV/EBITDA
12.25
P/E
17.19
EV/Sales
5.25
Sector
Personal Care Products
Category
growth
Giant Biogene (2367 HK) — Collagen as an Enduring Franchise
2367.HK: China's recombinant collagen leader w/ 80%+ gross margins from proprietary yeast-expression tech. Dual medical/aesthetic model: hospital wound care (stable) + premium dermaceuticals (growth). Regulatory moat via patents & hospital relationships. Risks: policy price cuts, macro softness in aesthetics.
Read full article (2 min)